"Virginia Eye Institute (VEI) is a comprehensive eye care organization providing a wide range of ophthalmology, optometry, and optical services in 8 locations across Central Virginia. VEI offers an exceptional range of ophthalmic care including, cornea and external diseases, glaucoma, cataract surgery, retina, oculoplastics, pediatrics, refractive surgery (LASIK), and general ophthalmology. All optometrists and ophthalmologists at VEI are board-certified and many are fellowship-trained. VEI eyewear locations provide board-certified opticians and contact lens fitters. VEI’s NEW Hearing Center is now open with a full range of testing and hearing services. We offer the most technologically advanced hearing instruments with unparalleled service."

During the past decade, Virginia Eye Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Eye Institute" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Aerie Pharmaceuticals" with 1 trials sponsored, "NYU Langone Health" with 1 trials sponsored, "Notal Vision Inc." with 1 trials sponsored and "Robert Feldman" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 1 trials as a collaborator and "National Institutes of Health (NIH)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Eye Institute" are "Geographic Atrophy" (2 trials), "Dry Eye Disease" (1 trials), "Glaucoma" (1 trials), "Herpes Zoster Ophthalmicus" (1 trials) and "Neovascular Age-related Macular Degeneration" (1 trials). Many other conditions were trialed in "Virginia Eye Institute" in a lesser frequency.

Most popular intervention types in "Virginia Eye Institute" are "Drug" (4 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lampalizumab" (2 trials), "AR-15512 Ophthalmic Solution" (1 trials), "Ahmed Model FP7 Flexible Plate" (1 trials), "Baerveldt Glaucoma Implant 250-mm2 / BG103-250" (1 trials) and "Baerveldt Glaucoma Implant 350-mm2 / BG101-350" (1 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Eye Institute" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Virginia Eye Institute". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Virginia Eye Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Eye Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".